T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Top advances of the year: Genitourinary cancer.
TL;DR: The use of triplet combinations with immune checkpoint inhibition with anti-vascular endothelial growth factor tyrosine kinase inhibitors in the front-line setting for metastatic disease (COSMIC313) has been explored as discussed by the authors .
Multicenter S tudy o f H uman I mmunodeficiency Virus-Related G erm C ell T umors
Thomas Powles,Mark Bower,Gedske Daugaard,Jonathan Shamash,A. De Ruiter,Margaret A. Johnson,M Fisher,Jane Anderson,S Mandalia,Justin Stebbing,Mark T. Nelson,Brian Gazzard,T. Oliver +12 more
TL;DR: Testicular seminoma occurs significantly more frequently in HIV-positive men than in the matched control population and should be treated in a similar manner to those in the HIV-negative population.
Journal ArticleDOI
Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.
Laurence Albiges,Katy Beckermann,Wilson H. Miller,Jeffrey C. Goh,Pablo Gajate,Carole A. Harris,Cristina Sáez,Avivit Peer,Se Hoon Park,Walter M. Stadler,Andrew Weickhardt,Guy Faust,Peter C.C. Fong,T. Waddell,Balaji Venugopal,Lina Yin,Ding Wang,Rodolfo F. Perini,Thomas Powles +18 more
TL;DR: In this article , the authors presented preliminary results from arm B5 for the belzutifan + lenvatinib combination, which exhibited promising antitumor activity in patients with CCRCC that progressed on PD-1/L1 inhibitors and VEGF-TKIs.
Journal ArticleDOI
1779TiP Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)
Vadim S. Koshkin,Thomas Powles,Gopa Iyer,Yohann Loriot,Alexandra Drakaki,Ignacio Duran Martinez,Maria De Santis,Margitta Retz,Rohit Jain,Shen Chan,Michito Ichimaru,Matthew D. Galsky +11 more
TL;DR: In this article , Disitamab vedotin (DV) is an investigational antibody-drug conjugate (ADC) comprised of a HER2-directed monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a protease-cleavable linker.
ORIGINAL RESEARCH Outcome in AIDS-Related Systemic Non-Hodgkin Lymphoma and Leptomeningeal Disease Is Not Predicted by a CT Brain Scan
TL;DR: A CT brain scan appears not to offer additional prognostic information following a lumbar puncture in patients with ARL, and when defined by the presence of abnormal enhancement or parenchymal lesions on a CT scan, the outcome was not significantly different.